INTRODUCTION
In patients with acute leukemia (AL) at high risk of relapse because of unfavorable cytogenetics, molecular markers and disease status (CR≥2), the most powerful post-remission therapy is hematopoietic stem cell transplantation (HSCT) from a matched sibling (MSD) or unrelated donor (MUD) (1, 2) . When patients do not have a MSD or MUD, unrelated cord blood (UCB) (3) and haploidentical-related donor (haplo) (4) HSCTs are emerging as alternatives.
In eradicating malignancy, i.e. the so-called graft-vs-leukemia effect (GvL), clinical observations (5, 6 ) and experimental models (7) (8) (9) established that the allogeneic immune system played a crucial role. Donor T cells recognize host allo-antigens on leukemic cells, although hematopoietic-specific and leukemia-specific responses may also occur (10) . They also mediate graft-vs-host disease (GvHD), a major cause of morbidity and mortality after HSCT.
In T cell replete HSCT pharmacological immunosuppression for GvHD prophylaxis and treatment is non-specific and only partially successful. More importantly, it may compromise the T-cell induced GvL effect. Indeed relapse is still the major cause of treatment failure in high risk AL patients (11) (12) (13) (14) .
To date, attempts to manipulate alloreactive T cells to spare normal cells while killing leukemic cells have been largely unsuccessful. In the search for strategies to separate GvHD and the GvL effect and prevent disease recurrence, attention focused on a thymic-derived CD4+CD25+ FoxP3+ regulatory T-cell subpopulation (Tregs) which physiologically helps maintain immunological selftolerance and immune homeostasis (15, 16) . Evidence from murine models of bone marrow transplantation across major histocompatibility class I and II barriers showed that co-infusion of conventional T lymphocytes (Tcons) with Tregs, whether freshly isolated (17) (18) (19) , ex vivo expanded polyclonal (20) or recipient-type (21) , suppressed lethal GvHD without impairing Tcon activity against malignant diseases (22, 23) . In high-risk AL patients undergoing full-haplotype mismatched transplantation without any post-transplant immunosuppression we demonstrated that For personal use only. on . by guest www.bloodjournal.org From adoptive immunotherapy with donor FoxP3+ T regs (2x10 6 /kg) and broad repertoire Tcons (1x10 6 /kg) almost completely prevented acute and chronic GvHD and favoured post-transplant immunological reconstitution (24) .
To address the issue of leukemia relapse, the present study investigated whether Treg-Tcon adoptive immunotherapy provided a powerful Tcon-mediated GvL effect in the absence of GvHD.
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PATIENTS AND METHODS

Patient inclusion criteria
The protocol was approved by Umbria Regional Hospital Ethical Committee and registered as 0108. Adults (18-65 years) with high risk AL were eligible for haplo-HSCT with Treg-Tcon adoptive immunotherapy if they did not have an MSD or MUD. Before enrolment all patients provided written informed consent in accordance with the Declaration of Helsinki.
Donors
A healthy family member with one HLA-haplotype identical to the patient's, who was able to donate haematopoietic stem cells after treatment with G-CSF and undergo leukapheresis sessions for collecting hematopoietic stem cells, Tregs and Tcons. An NK alloreactive donor was preferentially selected when available (Table 1) . Figure 1 illustrates the transplant timeline schema. Briefly, the conditioning regimen included total body irradiation (TBI), thiotepa, fludarabine. The first 25 patients also received cyclophosphamide.
Transplantation Procedure
To reduce extra-hematological toxicity and the risk of veno-occlusive disease instead of cyclophosphamide the other 18 were given alemtuzumab (8 patients) or thymoglobulin (12 patients) when alemtuzumab was withdrawn for patients with haematological diseases. Anti-T antibodies were administered 21 days before transplant to prevent interference with Treg-Tcon adoptive immunotherapy. All patients received freshly isolated donor Tregs on day -4, followed by a megadose of purified CD34+ cells and Tcons on day 0. The 4-day interval between Treg and Tcon infusions was in accordance with animal data indicating that early Treg administration provided greatest protection against GvHD (18) . No pharmacological post-transplant GvHD prophylaxis was given. Patients were managed according to our standard haplo-HSCT protocol (25) 
Graft processing
Tregs and Tcons were collected from donors before they underwent G-CSF treatment for CD34+ cell collection. 2 total blood volumes from a single leukapheresis procedure were processed with COBE Spectra (Terumo BCT, CO, USA).Tcons were separated from peripheral blood mononuclear cells (PBMCs) by negative selection using CliniMACS CD19 reagent (Miltenyi Biotec), and cryopreserved (24) . Naturally occurring CD4+CD25+ FoxP3+ Tregs were selected by means of a fully automated immunomagnetic procedure (Miltenyi Biotec GmbH, Bergisch Gladbach Germany) by depleting the leukapheresis product of CD8+/CD19+ cells and then positively immunoselecting CD25+cells (24) . The initial leukapheresis products contained a median of 12.1x10 9 (range 5.4-18x10 9 ) nucleated cells. After magnetic cell separation a median of 272x10 6 (range 142-412x10 6 ) Tregs was recovered.
Immediately after Treg and Tcon collection, donors were treated with G-CSF to mobilize peripheral blood progenitor cells. After collection, CD34 + cells were positively immunoselected using the CliniMACS device (Miltenyi Biotec) (25) . The target numbers of Tregs, Tcons and CD34+ cells were achieved for all patients (see below). Phenotypes were determined using direct immunofluorescence with a panel of monoclonal antibodies as described before (24) . Overall 3 days of apheresis were needed for each donor (1 for Treg and Tcon collection; 2 for CD34+ cells). 
Suppression assays
CD4+CD25-T cells alone).
Chimerism analysis and immunological studies
Chimerism was assessed on DNA extracted from peripheral blood samples by multiplex fluorescent short-tandem repeat analysis. Peripheral blood was collected weekly for the first two months and then monthly for cytometric lymphocyte subset immunophenotyping. Alloreactive NK cell subsets were phenotyped in donors and monthly in recipients after transplant. Function was analysed in cytotoxicity assays against KIR ligand mis-matched recipient target cells to determine the frequency of alloreactive NK clones (24) . For personal use only. on January 12, 2018. by guest www.bloodjournal.org From
End-points and definitions
Historical controls
We compared outcomes of the present Treg-Tcon transplants with 114 high risk CR1, ≥ CR2 AL patients (50 ALL; 64 AML; median age 37 years) (Table 1) 
Statistical analyses
Cumulative incidence estimates (evaluated by the Gray test) were used for relapse and nonleukemic mortality, as they are competing risks. The Kaplan-Meier method evaluated EFS. The logrank test assessed impact of disease (AML v ALL), disease status, gender, age, pre-transplant donor-recipient pair CMV, donor-recipient NK cell on EFS. Multivariate analysis (Cox regression model) also investigated the impact of these factors on non-leukemic mortality, relapse and EFS.
Two-sided P values <.05 were considered significant.
Mouse models
Colonies of NOD-scidIl2rgtm (NSG) mice were bred at Perugia University Animal House. All experiments were performed in accordance with the National Ethic Approval Document for animal experimentation.
NSG mice were irradiated with 3. 
Twenty-four of these patients have already been reported in a previous paper (24) . All patients who were transplanted in CR1 were at high risk of relapse (8 FLT-3/ITD; 8 complex karyotypes; 4 with t(9:22); 2 primary induction failure; 1 secondary AML; 1 CR after second-line induction; 1 with central nervous system (CNS) and skin involvement at diagnosis). to the 11% in historical controls. They had received extensively T cell depleted grafts and ATG which exerted additional in vivo T cell depletion. Three patients (7.5%) died of GvHD (1 grade II aGvHD. 2 grade III-IV aGvHD) compared with 10 (9%) in the historic cohort.
Overall in the present series, the cumulative incidence of NRM was 0.40 which fell to 0.21 in 18
patients who received anti-T antibodies in the conditioning. Causes of non-relapse death were:
veno-occlusive disease in 3 patients who were heavily pre-treated until a few days before transplantation, GvHD (3), adenoviral infection (2), bacterial sepsis (2), HHV6 infection (2), multiorgan failure (1), systemic toxoplasmosis (1). Lung (3) and CNS (1) aspergillosis in patients with invasive fungal disease before transplantation. 
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Human T cells from bone marrow in mice that were rescued from leukemia by Treg-Tcon adoptive immunotherapy exhibited similar cytoxicity against both leukemic and PHA blast cells, autologous to leukemia (Fig 3) . This experiment was repeated twice. Immunological reconstitution in our transplant recipients was stronger and faster than in the historical controls.
Prevention of CMV disease improved markedly, with no CMV-related deaths which had been one of the major causes of mortality in the historical control group.
Overall NRM is still unsatisfactory in the present series but it is interesting to note it dropped sharply in patients who received anti-T antibodies in the conditioning regimen. Better outcomes may have been linked to cyclophosphamide suspension as less extra-medullary toxicity was associated with lack of severe VOD and multi-organ failure. In the future to reduce the risk of posttransplant infection-related morbidity and mortality, it might be worth increasing the number of Tcons in the graft by means of CD3+CD45RO+ cells (29) , thus approaching what is termed a "designed" graft for haploidentical transplantation (30) .
One major concern about the use of Tregs in HSCT is their potential to suppress anti-neoplastic immune responses, as suggested by some studies in solid tumors (31, 32) In the present series of AL patients, infusion of Tcons under the Treg protective umbrella, in the absence of post-transplant pharmacological immunosuppression guaranteed almost total control of AML and ALL relapse. The cumulative incidence of post-transplant leukemia relapse was 0.05 at a medium follow-up of 46 months, which is extremely low considering these patients were at highrisk of relapse according to cytogenetics, molecular markers and disease stage at transplant. In our historical controls relapse rates were over 30% in high-risk ALL patients and in AML patients who were not transplanted from NK alloreactive donors. Similarly, relapse rates ranged from 28% to 40% in recent clinical trials of T cell replete HSCT, independently of whether the donor was a MSD, MUD, UCB or haplo (11) (12) (13) (14) . In the present series the T-cell dependent GvL effect was so powerful that it masked the anti-AML activity exerted by post-transplant generation of alloreactive donor-vs-recipient NK cell repertoires (37-39).
The mechanisms underlying Treg suppression of GvHD with no loss of GvL activity are still obscure. In animal models Edinger et al observed that Tregs inhibited early expansion of alloreactive donor T cells and their capacity to induce GVHD but did not inhibit co-transplanted Tcon activation and cytotoxicity against leukemia and lymphoma cells in vitro and in vivo. Thus GvL activity appears to rely mainly on Tcon activation rather than expansion and consequently requires transplantation of sufficient Tcons (22) 
In our murine models human T cells that were harvested from bone marrow killed human leukemia cells and autologous PHA blasts in vitro, thus confirming their cytotoxicity activity was preserved and suggesting the T cell dependent GvL effect is mainly due to alloantigen recognition.
The GvL effect in the absence of GvHD could also be related to Treg migratory properties which are linked to expression of homing molecules for diverse sites. Tracking Treg in vivo dynamics in animal models of incompatible transplantation showed that upon infusion of polyclonal Tregs alloantigen-specific Treg were activated and expanded in lymph nodes and then migrated to peripheral tissues (skin, gut, liver, lung) (18) . Thus alloantigen-specific Tregs controlled Tcon alloreactivity not only in lymph nodes but in non-lymphoid tissues which are GvHD targets.
In the clinical transplant setting, one might hypothesize the GvL effect is due to largely unopposed For personal use only. on January 12, 2018. by guest www.bloodjournal.org From
In conclusion we are confident the innovative use of Tregs and Tcons is a major advance on conventional HSCT which, as leukemia immunotherapy, is associated with severe side effects and is only partially efficacious. In the future the present strategy might be applied to exploit the GvL effect of Tcons that recognize minor histocompatibility antigens in matched donor HSCT. 7 3 33 (77%) 18 15 50 (44%) 27 23 
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